Myopathy in certain specified endocrine disease (Q41409): Difference between revisions
From determinar.ia.br - Determine suas informações
Created a new Item |
Changed an Item |
||||||||||||||
| (7 intermediate revisions by the same user not shown) | |||||||||||||||
| description / pt-br | description / pt-br | ||||||||||||||
Miopatia em algumas doenças endócrinas especificadas refere-se a transtornos musculares associados a disfunção adrenal (como miopatia esteroide), disfunção tireoidiana (como em coma mixedematoso ou miopatia tireotóxica), disfunção paratireoide (como em neoplasia endócrina múltipla), disfunção hipofisária e disfunção de ilhas de Langerhans (como na miopatia diabética por infarto isquêmico dos músculos femorais). A miopatia relacionada a esteroides é a miopatia endócrina mais comum. Essas condições são geralmente reversíveis com a correção do distúrbio endócrino subjacente. | |||||||||||||||
| description / en | description / en | ||||||||||||||
Myopathy in certain specified endocrine disease refers to muscle disorders associated with adrenal dysfunction (as steroid myopathy), thyroid dysfunction (as in myxoedema coma or thyrotoxic myopathy), parathyroid dysfunction (as in multiple endocrine neoplasia), pituitary dysfunction, and islands of Langerhans dysfunction (as in diabetic myopathy from ischemic infarction of the femoral muscles). Steroid myopathy is the most common endocrine myopathy. These conditions are usually reversible with correction of the underlying endocrine disturbance. | |||||||||||||||
| Property / Canonical URI | |||||||||||||||
| Property / Canonical URI: https://id.who.int/icd/entity/946840192 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / CURIE | |||||||||||||||
CID11:8C83 | |||||||||||||||
| Property / CURIE: CID11:8C83 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Canary Token | |||||||||||||||
dki-india-8C83 | |||||||||||||||
| Property / Canary Token: dki-india-8C83 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Verification Status | |||||||||||||||
Concluído | |||||||||||||||
| Property / Verification Status: Concluído / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Knowledge Architect | |||||||||||||||
| Property / Knowledge Architect: https://pauloleads.com.br/cases-publicos/ / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Collection date | |||||||||||||||
13 August 2026
| |||||||||||||||
| Property / Collection date: 13 August 2026 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Linked ICD 10 | |||||||||||||||
| Property / Linked ICD 10: G72 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Latest revision as of 07:34, 13 August 2026
Myopathy in certain specified endocrine disease refers to muscle disorders associated with adrenal dysfunction (as steroid myopathy), thyroid dysfunction (as in myxoedema coma or thyrotoxic myopathy), parathyroid dysfunction (as in multiple endocrine neoplasia), pituitary dysfunction, and islands of Langerhans dysfunction (as in diabetic myopathy from ischemic infarction of the femoral muscles). Steroid myopathy is the most common endocrine myopathy. These conditions are usually reversible with correction of the underlying endocrine disturbance.
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | 8C83 |
||
| English | Myopathy in certain specified endocrine disease |
Myopathy in certain specified endocrine disease refers to muscle disorders associated with adrenal dysfunction (as steroid myopathy), thyroid dysfunction (as in myxoedema coma or thyrotoxic myopathy), parathyroid dysfunction (as in multiple endocrine neoplasia), pituitary dysfunction, and islands of Langerhans dysfunction (as in diabetic myopathy from ischemic infarction of the femoral muscles). Steroid myopathy is the most common endocrine myopathy. These conditions are usually reversible with correction of the underlying endocrine disturbance. |
Statements
CID11:8C83
0 references
dki-india-8C83
0 references
Concluído
0 references
13 August 2026
0 references
